ConductScience.org, home

Paper23442

Acetohydroxamic acid: clinical studies of a urease inhibitor in patients with staghorn renal calculi.

Griffith DP and 3 others. J Urol, 1978. Cited by 108 papers, by iCite.

Cite this record

ConductScience Library. Acetohydroxamic acid: clinical studies of a urease inhibitor in patients with staghorn renal calculi. Papers, record 23442. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23442

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Acetohydroxamic acid: clinical studies of a urease inhibitor in patients with staghorn renal calculi.
PubMed
Journal
J Urol
PubMed
Year
1978
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
108
iCite
Relative citation ratio, by iCite
5.62
iCite
Revised in PubMed
2019-06-21
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Griffith DPD P
2Gibson JRJ R
3Clinton CWC W
4Musher DMD M

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hydroxamic AcidsMajor topic
Kidney CalculiMajor topic
UreaseMajor topic
Ammonia
Humans
Hydrogen-Ion Concentration
Hydrolysis
Kinetics
Urea
Urinary Tract Infections

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT07393438Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)Background

Source ClinicalTrials.gov

Download CSV of trials

Cited by24

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 108 citations.

PMIDTitleJournalYearIn PapersSource
42631197FDA approved drug containing acetamide group- a mini review.Front Chem2026https://conductscience.org/library/papers/42631197PubMed
42290516Urease inhibitors: current advances, therapeutic potentials, and clinical challenges.Future Med Chem2026https://conductscience.org/library/papers/42290516PubMed
38681280Prognostic Factors for Residual Lithiasis in Patients With Staghorn Calculi Undergoing Percutaneous Nephrolithotomy in the Maya Region of Yucatan, Mexico: A Case-Control Study.Cureus2024https://conductscience.org/library/papers/38681280PubMed
38516598In vitro biological evaluation and in silico studies of linear diarylheptanoids from Curcuma aromatica Salisb. as urease inhibitors.RSC Med Chem2024https://conductscience.org/library/papers/38516598PubMed
36985670Unraveling Binding Mechanism and Stability of Urease Inhibitors: A QM/MM MD Study.Molecules2023https://conductscience.org/library/papers/36985670PubMed
34062878Zerumbone Inhibits Helicobacter pylori Urease Activity.Molecules2021https://conductscience.org/library/papers/34062878PubMed
33553205Encrusted Uropathy: A Comprehensive Overview-To the Bottom of the Crust.Front Med (Lausanne)2020https://conductscience.org/library/papers/33553205PubMed
33005194Urinary Calculi: A Microbiological and Biochemical Analysis at a Tertiary Care Hospital in Eastern Nepal.Int J Microbiol2020https://conductscience.org/library/papers/33005194PubMed
32719668Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections.Front Microbiol2020https://conductscience.org/library/papers/32719668PubMed
32257805Metabolic evaluation and medical management of staghorn calculi.Asian J Urol2020https://conductscience.org/library/papers/32257805PubMed
24497689Standardizing the reporting of percutaneous nephrolithotomy complications.Indian J Urol2014https://conductscience.org/library/papers/24497689PubMed
20449779[Urinary tract infections and Urolithiasis].Urologe A2010https://conductscience.org/library/papers/20449779PubMed
17848149Using verapamil as protective factor in renal ischemia reperfusion injury during anatrophic nephrolithotomy.Bosn J Basic Med Sci2007https://conductscience.org/library/papers/17848149PubMed
15614579Encrustation of biomaterials in the urinary tract.Urol Res2005https://conductscience.org/library/papers/15614579PubMed
6737406Bacteriological and crystallographical analysis of urinary calculi: aid to patient management.J R Soc Med1984https://conductscience.org/library/papers/6737406PubMed
6480281Applicability of biosuppressin as an urease-inhibitor.Int Urol Nephrol1984https://conductscience.org/library/papers/6480281PubMed
6401560Prospects for prevention.Br Med J (Clin Res Ed)1983https://conductscience.org/library/papers/6401560PubMed
6119364Urinary tract infection.J R Coll Physicians Lond1981https://conductscience.org/library/papers/6119364PubMed
3928387Pharmacokinetics of acetohydroxamic acid in patients with staghorn renal calculi.Eur J Clin Pharmacol1985https://conductscience.org/library/papers/3928387PubMed
3771124S.E.M. study of urease-induced crystalluria in the presence of hydroxamic derivatives.Int Urol Nephrol1986https://conductscience.org/library/papers/3771124PubMed

See all 24 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/23442

GET https://conductscience.org/api/papers/v1/23442/cited_by?page=2